 Cost benefit secondary prophylaxis Pneumocystis carinii pneumonia OBJECTIVE relative cost benefit aerosolized pentamidine combination product sulfamethoxazole trimethoprim sulfate secondary prophylaxis Pneumocystis carinii pneumonia DESIGN Markov-based cost-benefit analysis Drug efficacies toxicities mortality rates current literature SETTING Hypothetical PATIENT POPULATION Patients human immunodeficiency virus episode carinii pneumonia INTERVENTIONS use aerosolized pentamidine sole first-line prophylactic agent patients Regimen use sulfamethoxazole-trimethoprim patients history toxic reaction drug patients history toxic effects toxic effects drug aerosolized pentamidine secondary prophylaxis MAIN OUTCOME MEASURES Net cost median patient survival survival regimen regimens regimen MAIN RESULTS dominant net cost patient median survival years prophylaxis regimen savings patient increase median survival regimen regimen savings increase median survival CONCLUSIONS Secondary prophylaxis carinii money survival Current data suggest sulfamethoxazole-trimethoprim Use aerosolized pentamidine first-line agent modest increase cost decrease life expectancy